B. Feagan
Genetics · 2000–2017
A researcher in the Science corpus: 28 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 127 citations into it; #3,131 of 6,854 by trust here, #166 by citations
Whom B. Feagan trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts B. Feagan overall
Papers from B. Feagan's perspective
Ordered by how strongly the researchers B. Feagan trusts endorse each paper. Same corpus, a different order for every researcher.
- Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. (Gastroenterology)
- The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. (Gastroenterology)
- The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. (Gastroenterology)
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (American Journal of Gastroenterology)
- Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. (Clinical Gastroenterology and Hepatology)
- Inflammatory bowel disease: clinical aspects and established and evolving therapies (The Lancet)
- Increased expression of interleukin 17 in inflammatory bowel disease (Gut)
- Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
- Breaking the matches in a paired t-test for community interventions when the number of pairs is small.
- The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. (Gastroenterology)
Their papers
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis (2017) — 877 citations
- Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. (2016) — 1,455 citations
- The safety of vedolizumab for ulcerative colitis and Crohn's disease (2016) — 763 citations
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target (2015) — 1,734 citations
- C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis (2015) — 621 citations
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. (2014) — 692 citations
- Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. (2014) — 920 citations
- Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. (2014) — 718 citations
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (2013) — 2,298 citations
- Vedolizumab as induction and maintenance therapy for Crohn's disease. (2013) — 2,088 citations
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry (2012) — 772 citations
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial (2012) — 1,480 citations
- Ustekinumab induction and maintenance therapy in refractory Crohn's disease. (2012) — 1,077 citations
- Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. (2011) — 912 citations
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. (2008) — 1,148 citations
- A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. (2008) — 774 citations
- A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. (2007) — 1,217 citations
- Certolizumab pegol for the treatment of Crohn's disease. (2007) — 594 citations
- Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. (2007) — 631 citations
- Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. (2006) — 932 citations